PMID: 6171819Oct 1, 1981Paper

Dopaminergic modulation of adenylate cyclase stimulation by vasoactive intestinal peptide in anterior pituitary

Proceedings of the National Academy of Sciences of the United States of America
P OnaliE Costa

Abstract

The activation of adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] by vasoactive intestinal peptide (VIP) was used as a model to investigate the molecular mechanisms triggered by the occupancy of dopamine recognition sites in rat anterior pituitary. Dopamine failed to change the basal enzyme activity, but it inhibited the stimulation of adenylate cyclase elicited by VIP. Apomorphine, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, and 2-bromo-alpha-ergocryptine mimicked the effect of dopamine, whereas (-)-sulpiride and and classical neuroleptics antagonized it. Dopamine failed to modulate the activation of pituitary adenylate cyclase by prostaglandin E1, which does not increase prolactin secretion. From these results we infer that stimulation of D-2 (dopamine) receptors may affect pituitary secretion by inhibiting the activation of anterior pituitary adenylate cyclase by VIP or other secretagogues.

References

Jan 15, 1979·European Journal of Pharmacology·H S AhnM H Makman
Jul 15, 1976·Life Sciences·M TrabucchiL Frattola
Jan 11, 1979·Nature·J W Kebabian, D B Calne
May 1, 1979·European Journal of Pharmacology·D R Sibley, I Creese
Jan 1, 1978·Neuroendocrinology·M A Calabro, R M MacLeod
Jul 1, 1969·Proceedings of the National Academy of Sciences of the United States of America·U ZorJ B Field
Nov 1, 1970·Proceedings of the National Academy of Sciences of the United States of America·R M MacLeod, J E Lehmeyer
Mar 1, 1973·Archives of Biochemistry and Biophysics·P BöhlenS Udenfriend
Apr 1, 1974·Endocrinology·J A ClemensE C Kornfeld
Apr 1, 1974·Analytical Biochemistry·Y SalomonM Rodbell
Jun 1, 1980·The Journal of Pharmacy and Pharmacology·A E TheodorouC D Marsden
Sep 1, 1980·Neuroendocrinology·A EnjalbertC Kordon

❮ Previous
Next ❯

Citations

Sep 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·P SokoloffJ C Schwartz
Jan 1, 1992·Journal of Neural Transmission. General Section·P Onali, M C Olianas
Sep 10, 1982·European Journal of Pharmacology·I D Hirschhorn, M H Makman
Mar 25, 1983·European Journal of Pharmacology·P OnaliE Costa
Sep 10, 1984·Life Sciences·M Hadjiconstantinou, N H Neff
Dec 3, 1984·Life Sciences·J C Stoof, J W Kebabian
Jan 1, 1990·Life Sciences·B Drukarch, J C Stoof
Jan 1, 1994·Pharmacology & Therapeutics·D M Jackson, A Westlind-Danielsson
Jan 1, 1987·Neurochemistry International·P Seeman, D Grigoriadis
Jul 1, 1982·Molecular and Cellular Endocrinology·K P Ray, M Wallis
Nov 1, 1982·Molecular and Cellular Endocrinology·K P Ray, M Wallis
Jul 1, 1984·Molecular and Cellular Endocrinology·A M JuddR M MacLeod
Jun 1, 1984·Molecular and Cellular Endocrinology·K P Ray, M Wallis
May 1, 1985·Molecular and Cellular Endocrinology·K KoikeR M MacLeod
Jun 1, 1991·Molecular and Cellular Endocrinology·C BouvierR Collu
Jun 1, 1993·Molecular and Cellular Endocrinology·H ForgetR Collu
May 1, 1983·Brain Research Bulletin·H L Obata-TsutoY Ibata
Mar 1, 1984·Brain Research Bulletin·H L Obata-TsutoY Ibata
Oct 18, 2000·European Journal of Pharmacology·J N OakH H Van Tol
Apr 30, 1996·Proceedings of the National Academy of Sciences of the United States of America·C MissaleP Spano
Mar 1, 1991·Neuropharmacology·A Szmigielski, J Zalewska-Kaszubska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here